focus
LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.
The deal includes up to another $400 million in payments if certain milestones are met.
advertisement
Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Treatments for cramps don't cut it. Why aren't there better options?
Next article： What does generative AI mean for health care? We asked experts
Next article： What does generative AI mean for health care? We asked experts
